Optimization of microtubule-stabilizing triazolopyrimidines as therapeutics for Alzheimer's disease and related tauopathies

University Of Pennsylvania, Philadelphia PA

Investigators

Linked publications, trials & patents

Abstract

Statement of Work Specific activities overseen by the Brunden laboratory include: 1) testing of prodrugs in established HEK293 and neuron microtubule stabilization assays; 2) intravenous and oral pharmacokinetic testing of prodrugs to determine the rate of conversion of prodrugs to the desired active compound; 3) assessment of preferred prodrugs for pharmacodynamic effect in wild-type mice to establish the minimum effective dose and duration of compound effect; and 4) determination of preferred prodrug acute maximum tolerated dose and the no adverse effect dose after 3 weeks of dosing.